Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Q1 2019 Earnings Presentation
10 slides from Puma Biotechnology's earnings presentation, May 9, 2019
Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update May 9, 2019 Copyright 2019 Puma Biotechnology
Slide 2: Forward-Looking Safe Harbor Statement
Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward–looking statements and are based on the cur
Slide 3: Puma's Pharmacy and Distributor Network
Puma’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network Acaria Health Patients Accredo CVS Onco360 Diplomat Sites of Care Biologics Academic Hospitals Community Hospitals Specialty Distributor Network Physician Practices Other (VA, DoD) McKesson ASD / Oncology Supply Cardinal
Slide 4: $45.6 Million Net Revenue in Q1 2019
$45.6 Million Net Revenue in Q1 2019 QUARTERLY NET REVENUE (IN $MM) 61.1 50.8 52.6 45.6 36.0 20.1 6.1 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Copyright 2019 Puma Biotechnology 4
Slide 5: Bottles Sold By Quarter
Bottles Sold By Quarter BOTTLES SOLD BY QUARTER (SP+SD) 5,538 4,799 4,936 4,449 3,517 2,137 April 1,600 675 Q3-17 Q4-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 Q2-19 • SP = Specialty Pharmacy Network, SD = Specialty Distributor Network Copyright 2019 Puma Biotechnology 5
Slide 6: Time to First Dispense in Specialty Pharmacy Network
Time to First Dispense in Specialty Pharmacy Network PERCENT OF PATIENTS TIME TO FIRST DISPENSE 33% 26% 15% 7% 8% 4% 2% 2% 1% 1% 5 OR LESS 5 THROUGH 10 THROUGH 15 THROUGH 20 THROUGH 30 THROUGH 45 THROUGH 60 THROUGH 90 THROUGH 120 AND 10 15 20 30 45 60 90 120 GREATER 74% of patients receive their fir
Slide 7: 74% of Targeted Prescribers Reached
74% of Targeted Prescribers Reached CUMULATIVE TARGET WRITER REACH BY QUARTER 74% 69% 71% 66% 61% 54% 26% Q3-17 Q4-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 • Reach defined as physician detailed. • Numbers reported for historical quarters may be slightly different from previous statements due to data updates
Slide 8: Pierre Fabre License for NERLYNX in Europe
Pierre Fabre License for NERLYNX® in Europe March 2019 • Well established oncology commercial/medical infrastructure in breast cancer throughout Europe, based on Navelbine® (vinorelbine) • Pierre Fabre has commercial and development rights to neratinib in Europe and parts of North and Western Africa
Slide 9: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Expected Regulatory Region Partner Approval Australia / SE Asia • Approved in ITT population – Australia Israel • Q3 2019 Canada • Q3 2019 Greater China • 1H 2020 – China • Q4 2019 – Hong Kong • 1H 2020 – Taiwan Latin America • 1H 2020 – Mexico South America •
Slide 10: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update May 9, 2019 Copyright 2019 Puma Biotechnology